Abstract
Background and Objective: Oxycodone is a widely used opioid analgesic, the global use of which has increased several-fold during the last decade. This study was designed to determine the effect of age on the pharmacokinetics of intravenous oxycodone, with special reference to renal function in elderly patients.
Methods: We compared the pharmacokinetics of 5 mg of intravenous oxycodone in four groups of 10–11 patients, aged 20–40, 60–70, 70–90 years, undergoing orthopaedic surgery. Plasma concentrations of oxycodone and its noroxycodone, oxymorphone and noroxymorphone metabolites were measured for 24 hours with a liquid chromatography-tandem mass spectrometric method. The cytochrome P450 (CYP) 2D6 genotype of the patients was determined. Glomerular filtration rate (GFR) was estimated on the basis of the age, sex and serum creatinine concentration of the patient.
Results: The pharmacokinetics of oxycodone showed age dependency. In the oldest group, the mean area under the plasma concentration-time curve from time zero to infinity (AUC∞) of oxycodone was 80% greater (p < 0.001) and the apparent total body clearance of the drug from plasma (CL) was 34% lower (p < 0.05) than in the youngest group. The mean AUC∞ of oxycodone was also 30–41% greater in the oldest group than in the age groups of 60–70 and 70–80 years (p < 0.05). Oxycodone plasma concentrations from 8 hours post-dose were >2-fold higher (p < 0.01) in patients aged >80 years than in patients aged 20–40 years. Noroxycodone AUC∞ was increased in the oldest group compared with patients aged 20–40 and 60–70 years (p < 0.05). There were no significant sex-related differences in any of the pharmacokinetic parameters. Because 37 of the 41 patients were extensive metabolizers through CYP2D6, the effect of the CYP2D6 genotype on oxycodone pharmacokinetics could not be properly assessed. There was a linear correlation between GFR and CL (p < 0.01, coefficient of determination [r2] = 0.26), volume of distribution at steady state (p < 0.05, r2 = 0.19) and AUC∞ (p < 0.01, r2 = 0.29) of oxycodone.
Conclusions: Age is an important factor affecting the pharmacokinetics of oxycodone. Following intravenous administration of oxycodone, patients aged >70 years are expected to have, on average, 40–80% higher exposure to oxycodone than young adult patients. Because oxycodone pharmacokinetics are greatly dependent on the age of the patient, it is important to titrate the analgesic dose individually, particularly in the elderly.
Similar content being viewed by others
References
Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990; 47: 631–46
Kalso E, Pöyhiä R, Onnela P, et al. Oxycodone and morphine in postoperative pain. Acta Anaesthesiol Scand 1991; 35: 642–6
Saari TI, Grönlund J, Hagelberg NM, et al. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol 2010; 66: 387–97
Pöyhiä R, Seppälä T, Olkkola KT, et al. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992; 33: 617–21
Leow KP, Smith MT, Watt JA, et al. Comparative oxycodone pharmacokinetics in humans after intravenous, oral and rectal administration. Ther Drug Monit 1992; 14: 479–84
Leow KP, Smith M, Williams BE, et al. Single dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992; 52: 487–95
Paulozzi LJ. Opioid analgesic involvement in drug abuse deaths in American metropolitan areas. Am J Public Health 2006; 96: 1755–7
Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998; 64: 603–11
Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006; 79: 461–79
El-Tahtawy A, Kokki H, Reidenberg BE. Population pharmacokinetics of oxycodone in children 6 months to 7 years old. J Clin Pharmacol 2006; 46: 433–42
Kokki H, Rasanen I, Reinikainen M, et al. Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Clin Pharmacokinet 2004; 43: 613–22
Olkkola KT, Hamunen K, Seppälä T, et al. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. Br J Clin Pharmacol 1994; 38: 71–6
Pokela M-L, Anttila E, Seppälä T, et al. Marked variation in oxycodone pharmacokinetics in infants. Pediatr Anesth 2005; 15: 560–5
Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 2007; 82: 87–96
Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137–47
Neuvonen M, Neuvonen PJ. Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry. Ther Drug Monit 2008; 30: 333–40
Sistonen J, Fuselli S, Levo A, et al. CYP2D6 genotyping by a multiplex primer extension reaction. Clin Chem 2005; 51: 1291–5
Liukas A, Kuusniemi K, Aantaa R, et al. Plasma concentrations of oral oxycodone are greatly increased in the elderly. Clin Pharmacol Ther 2008; 84: 462–7
Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41: 67–76
Shi S, Mörike K, Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 2008; 64: 183–99
Kirvelä M, Lindgren L, Seppälä T, et al. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 1996; 8: 13–8
Kaiko R, Benziger D, Cheng C, et al. Clinical pharmacokinetics of controlled release oxycodone in renal impairment [abstract]. Clin Pharmacol Ther 1996; 59: 130
Purdue Pharma prescribing information on Oxycontin (oxycodone HCl controlled-release) tablets [online]. Available from URL: http://www.purduepharma.com/PI/Prescription/Oxycontin.pdf [Accessed 2010 Apr 21]
Zwisler ST, Enggaard TP, Mikkelsen S, et al. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand 2010; 54: 232–40
Acknowledgements
This study was supported by the Turku University Hospital Research Fund ♯13821, Turku University Foundation, Turku, Finland, Instrumentarium Research Foundation, Helsinki, Finland and the Sigrid Jusélius Foundation, Helsinki, Finland.
Klaus Olkkola has given expert testimony for Norpharma A/S Denmark concerning Oxycontin® and has been the recipient of an unrestricted research grant from Mundipharma Finland Inc. The other authors have no conflicts of interest that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liukas, A., Kuusniemi, K., Aantaa, R. et al. Elimination of Intravenous Oxycodone in the Elderly. Drugs Aging 28, 41–50 (2011). https://doi.org/10.2165/11586140-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11586140-000000000-00000